MedPath

FDA Grants Fast Track Designation to Lipocine's LPCN 1148 for Sarcopenia in Decompensated Cirrhosis

• The FDA has granted Fast Track designation to Lipocine's LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis. • Fast Track designation aims to expedite the development and review of drugs addressing serious conditions and unmet medical needs. • LPCN 1148 is being developed by Lipocine as a potential therapeutic option for sarcopenia, a muscle wasting condition, in the context of advanced liver disease.

Lipocine Inc. has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for LPCN 1148, a drug candidate aimed at treating sarcopenia in patients with decompensated cirrhosis. This designation, announced on December 17, 2024, is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill unmet medical needs.

Significance of Fast Track Designation

The FDA's Fast Track program is designed to accelerate the availability of new therapies for serious conditions. By granting Fast Track designation to LPCN 1148, the FDA recognizes the potential of this drug to address a critical unmet need in patients with decompensated cirrhosis who are suffering from sarcopenia. This designation provides Lipocine with opportunities for more frequent meetings and communication with the FDA during the drug development process, as well as the potential for accelerated approval and priority review if relevant criteria are met.

LPCN 1148: Addressing Sarcopenia in Decompensated Cirrhosis

LPCN 1148 is being developed as a potential treatment for sarcopenia, a condition characterized by loss of muscle mass and strength, which is often observed in patients with decompensated cirrhosis. Decompensated cirrhosis represents an advanced stage of liver disease where the liver is severely compromised, leading to complications such as ascites, hepatic encephalopathy, and variceal bleeding. Sarcopenia in this patient population is associated with increased morbidity and mortality, making it a significant clinical challenge.

Lipocine's Focus

Lipocine Inc. is a pharmaceutical company focused on developing innovative treatments for metabolic and endocrine disorders. The company's pipeline includes several drug candidates targeting conditions with significant unmet medical needs. The Fast Track designation for LPCN 1148 underscores the importance of addressing sarcopenia in patients with decompensated cirrhosis and highlights Lipocine's commitment to developing therapies for challenging medical conditions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Grants Fast Track Designation to Lipocine's LPCN 1148 for Sarcopenia in Decompensated Cirrhosis

The FDA has granted Fast Track designation to Lipocine's LPCN 1148 for treating sarcopenia in patients with decompensated cirrhosis, addressing an unmet medical need.
LPCN 1148, an oral prodrug of bioidentical testosterone, demonstrated improved sarcopenia and clinical outcomes in a Phase 2 proof-of-concept study.

Tonix Pharmaceuticals Bolsters Leadership Team and Provides Update on TNX-102 SL

Tonix Pharmaceuticals has appointed Bradley Raudabaugh as Vice President of Marketing and Errol Gould, Ph.D., as Vice President of Medical Affairs to support the potential launch of TNX-102 SL.
Enrollment for the TNX-102 SL OASIS study, which is evaluating the treatment of acute stress reaction and acute stress disorder, is expected to begin in Q1 2025.

MAIA Biotechnology's THIO-101 Shows Promising Survival Data in Advanced NSCLC

MAIA Biotechnology's THIO-101, sequenced with cemiplimab, demonstrates encouraging efficacy in advanced non-small cell lung cancer (NSCLC) patients who have failed multiple prior therapies.
Interim data from the Phase 2 THIO-101 trial reveals a median survival follow-up of 11.5 months in the third-line treatment group across all THIO dose levels.

FDA Extends Review of Organon's VTAMA for Atopic Dermatitis

The FDA has extended the target action date for reviewing Organon's supplemental New Drug Application for VTAMA (tapinarof) cream, 1%, to March 12, 2025.
This extension pertains to the treatment of atopic dermatitis in adults and children aged two years and older.

Cyclacel Completes Enrollment in Fadraciclib Trial for Tumors with CDKN2A/B Abnormalities

Cyclacel Pharmaceuticals completed enrollment in Cohort 8 of its Phase 2 trial of fadraciclib, a CDK2/9 inhibitor, focusing on patients with advanced solid tumors and lymphoma exhibiting CDKN2A/B abnormalities.
The rapid enrollment, completed in approximately six months, highlights the significant unmet need for cancer patients with these specific genetic aberrations.

CytoDyn Advances Leronlimab Pipeline Across Oncology, Inflammation, and HIV

CytoDyn's leronlimab sees renewed progress with the FDA lifting its clinical hold in March 2024, enabling the advancement of clinical trials.
A Phase II study of leronlimab in relapsed/refractory microsatellite stable colorectal cancer is set to begin screening patients in early 2025.

FDA Gears Up for Key Approval Decisions in Q4 2024

The FDA is set to decide on dasiglucagon for congenital hyperinsulinism, with a PDUFA date of October 8, potentially benefiting pediatric patients.
Nivolumab-based regimens for resectable NSCLC are under review, supported by Phase 3 data showing a 42% reduction in disease recurrence, with a PDUFA date of October 8.

FDA Grants Priority Review to Soleno's DCCR for Prader-Willi Syndrome

The FDA has accepted Soleno Therapeutics' NDA for DCCR, granting Priority Review for treating hyperphagia in Prader-Willi Syndrome (PWS) patients aged four and older.
A PDUFA target action date is set for December 27, 2024, with the FDA planning an advisory committee meeting to discuss DCCR's application.

FDA Advisory Committee to Review Lexicon's Sotagliflozin for Type 1 Diabetes and CKD

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Lexicon's Zynquista (sotagliflozin) on October 31, 2024.
Lexicon is seeking approval for sotagliflozin as an adjunct to insulin for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD).

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes and CKD

Lexicon Pharmaceuticals has resubmitted its New Drug Application (NDA) to the FDA for sotagliflozin, aiming to treat type 1 diabetes and chronic kidney disease.
The FDA has acknowledged the resubmission and set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2024, for its decision.

Reference News

[1]
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
quantisnow.com · Dec 18, 2024

LIPOCINE INC. filed a Form 8-K on December 17, 2024, announcing the FDA's Fast Track Designation for LPCN 1148 as a trea...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy